{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"This measure assessed how many participants have no LMB-100 plasma drug levels higher than threshold (600 ng/mL) during Cycle 3 pharmacokinetics (PK) measurements, a sign of effective prevention of anti-LMB-100 antibodies. The validated enzyme-linked immunosorbent assay (ELISA) test was used to measure plasma LMB-100 concentration. Below 600ng/mL is considered a bad outcome and above 600ng/mL is considered a good outcome.","groups":[{"description":"LMB-100 100 mcg/kg\n\nLMB-100: Arms 1: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 1: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG000","title":"Dose Escalation Dose Level 1 LMB-100 100 mcg/kg"},{"description":"LMB-100 140 mcg/kg\n\nLMB-100: Arms 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG001","title":"Dose Escalation Dose Level 2 LMB-100 140 mcg/kg"},{"description":"LMB-100 at optimal dose plus tofacitinib - 100 mcg/kg LMB-100: Arms 1: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.\n\nTofacitinib: Arms 1: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.","id":"OG002","title":"Dose Expansion LMB-100, 100 mcg/kg"}],"paramType":"NUMBER","populationDescription":"12/16 participants were not evaluable because they did not receive a 3rd cycle of treatment.","reportingStatus":"POSTED","timeFrame":"Plasma LMB-100 levels during Cycle 3 treatment (each cycle = 21 days)","title":"Percentage of Participants Without Delayed Formation of Neutralizing Anti-LMB-100 Anti-drug Antibodies (ADAs)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}